Biotech entity
pharma is the sole category represented across all 1 tracked stories. Sudarshan Jain is most often covered alongside Donald Trump, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Sudarshan Jain is most often covered alongside Donald Trump, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 6, the average consequence score sits above the same-window beat average of 5.7. Sudarshan Jain appears in 1 tracked Biotech story from August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Sudarshan Jain. Shared-story counts are live from our verified record — not editorial picks.
The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Source: heraldglobe.com · milwaukeesun.com
Sudarshan Jain is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
